Research report covers the Insulin Market Forecasts, 2017 - 2021

Diabetes is a group of metabolic diseases that has taken the centre stage across the world as one of the most profound and lasting conditions that significantly reduces the quality of life for people. It has grown to epidemic proportions and approximately 400 million people currently live with diabetes across the world and this number is expected to expand to approximately 550 million by 2030. There are two types of diabetes (Type 1 & Type 2). Type-1 is characterized by the inability of the body to produce insulin, the hormone that is needed to convert sugar, starches and other food into energy. It is a peptide hormone responsible for regulating the blood glucose levels. Though there is no well defined aetiology for occurrence of type 1 diabetes, it is mostly associated with genetic disorder or unexpected immune system's reaction that erroneously destroys the insulin producing cells of islet. Major symptoms include feeling thirsty, frequent urination, constant fatigue, weight loss and muscle loss, slow wound healing, blurred vision and repeated episodes of thrush. Many people have type 2 diabetes for years without realising because the early symptoms tend to be general. Type 2 diabetes is where the body doesn't produce enough insulin, or the body's cells don't react to insulin. This is known as insulin resistance. This form of diabetes is far more common than type 1 diabetes.

The only treatment widely recommended by medical practitioners is insulin intake for the lifetime. HbA1c test is considered as a critical test to infer the presence of glucose in the blood for the past couple of months and also plays an important role in laying down the treatment regime specific to individual patients. Insulin treatment algorithm can be defined on the basis of insulin preferred by the physicians that would give maximum efficacious outputs to the patient. The broad classification of types of insulin is based on their onset of action and duration of action - rapid acting, short acting, long acting, intermediate acting and pre-mixed insulin. Giant pharmaceutical companies like Novo Nordisk, Eli Lilly and Sanofi are the key players in this market with Novo Nordisk being the market leader.

Free Sample Report@ http://www.sa-brc.com/Global-Insulin-Market-Assessment--Forecast-2017-2021/up29

Insulin market is also categorized on the basis of its origin and technological advancement achieved in delivering the drug to the human body. Prefilled insulin delivering devices currently govern approximately two-third of the total insulin volume injected to human beings globally. Insulin derived from human origin takes up the maximum market share compared to insulin derived from animal sources. The new category of insulin called as modern insulin widely known as insulin analogues that are produced through recombinant DNA technology is expected to lead the future market enabling patients to have better glycaemic control.

Lantus from Sanofi is a leading product in long acting insulin segment competing with Levemir from Novo Nordisk. Other key products in this market are - Humalog, Novolog, Apidra, Velosulin, NPH, Lente, Humilin, Novolin, etc. New devices such as insulin pumps are making lives easier since patients do not have to constantly bother with injections. These devices and a new class of devices called artificial pancreas are expected to reduce patient discomfort and improve the quality of life for diabetics significantly. Though North America is the largest insulin market followed by Europe, tremendous growth has been identified in Asia precisely in India and China due to large diabetic population diagnosed in this region. Other emerging geographic regions for insulin drugs market with reasonable growth rate are Latin America, Middle East and Africa.

Click For TOC@ http://www.sa-brc.com/Global-Insulin-Market-Assessment--Forecast-2016---2020/upcomingdetail29

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.